检索结果-南通市图书馆

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients:A 12-week randomized placebo-controlled phase III trial with long-term extension

引用

Chinese Medical journal 2024年第10期137卷 1190-1198页

作者： Chen Yu Songmei Geng Bin Yang Yunhua Deng Fuqiu Li Xiaojing Kang Mingye Bi Furen Zhang Yi Zhao Weili Pan Zhongwei Tian Jinhua Xu Zhenghua Zhang Nan Yu Xinsuo Duan Shuping Guo Qing Sun Weiquan Li Juan Tao Zhijun Liu Yuanyuan Yin Gang Wang Department of dermatology Xijing HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710032China Department of dermatology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China Department of dermatology Dermatology Hospital of Southern Medical UniversityGuangzhouGuangdong 510091China Department of dermatology Tongji HospitalHuazhong University of Science and TechnologyWuhanHubei 430030China Department of dermatology The Second Hospital of Jilin UniversityChangchunJilin 130041China Department of dermatology People’s Hospital of Xinjiang Uygur Autonomous RegionUrumqiXinjiang 830001China Department of dermatology Wuxi People’s Hospital of Wuxi CityWuxiJiangsu 214023China Department of dermatology Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and VenereologyShandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China Department of dermatology Beijing Tsinghua Changgung HospitalBeijing 102218China Department of dermatology Zhejiang Provincial People’s HospitalHangzhouZhejiang 310014China Department of dermatology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100China Department of dermatology Huashan Hospital Affiliated to Fudan UniversityShanghai 200040China Department of dermatology General Hospital of Ningxia Medical UniversityYinchuanNingxia 750000China Department of dermatology Affiliated Hospital of Chengde Medical UniversityChengdeHebei 067000China Department of dermatology The First Hospital of Shanxi Medical UniversityTaiyuanShanxi 030001China Department of dermatology Qilu Hospital of Shandong UniversityJinanShandong 250012China Department of dermatology Yuebei People’s HospitalShaoguanGuangdong 512026China Department of dermatology Union Hospital Tongji Medical Collage Huazhong University of Science and TechnologyWuhanHubei 430022China Department of dermatology and Venereal Diseases The First Affiliated Hospit

Background:There is a need for effective and safe therapies for psoriasis that provide sustained *** aim of this study was to assess the efficacy and safety of tildrakizumab,an anti-interleukin-23p19 monoclonal antibody,for treating moderate-to-severe plaque psoriasis in Chinese ***:In this multi-center,double-blind,phase III trial,patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned(1:1)to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and *** initially assigned to placebo were switched to receive tildrakizumab at weeks 12,16,and every 12 weeks *** in the tildrakizumab group continued with tildrakizumab at week 16,and every 12 weeks until week *** primary endpoint was the Psoriasis Area and Severity Index(PASI 75)response rate at week ***:At week 12,tildrakizumab demonstrated significantly higher PASI 75 response rates(66.4%[73/110]vs.12.7%[14/110];difference,51.4%[95%confidence interval(CI),40.72,62.13];P<0.001)and Physician’s Global Assessment(60.9%[67/110]vs.10.0%[11/110];difference,49.1%[95%CI,38.64,59.62];P<0.001)compared to *** 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups,reaching maximal efficacy after 28 weeks(86.8%[92/106]vs.82.4%[89/108])and maintained up to 52 weeks(91.3%[95/104]vs.87.4%[90/103]).Most treatment-emergent adverse events were mild and not related to ***:Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque *** registration:***,NCT05108766.

关键词： Tildrakizumab Interleukin 23 Plaque psoriasis Chinese Randomized controlled trial

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Cutibacterium acnes in Atopic Dermatitis:Roles and Potential Therapeutic Applications

引用

International journal of dermatology and Venereology 2024年第1期7卷 12-17页

作者： Tian-Ze Yu Wei Li Department of dermatology Shanghai Institute of DermatologyHuashan HospitalFudan UniversityShanghai 200040China

Atopic dermatitis(AD)is a chronic relapsing inflammatory skin *** main initiating mechanisms of AD are disruptions in the skin microbiota,dysfunction of the skin barrier,and predominantly elevated type 2 immune *** acnes(***)is a commensal bacterium that is ubiquitous and predominant in healthy skin and shows intraspecific subtype *** abundance of *** is closely related to the sebum secreted by sebaceous *** has long been considered a proinflammatory skin bacterium that drives the development of acne *** evidence indicates that *** promotes skin microbiota homeostasis and skin barrier maintenance;however,the potential role of *** in AD remains largely *** review provides the latest information on the distribution of *** and its phylotypes in healthy skin and AD as well as an overview of the possible role of *** in the pathophysiological pathways underlying ***,the review focuses on new evidence regarding the protective functions of *** and its metabolites in AD and discusses the potential for therapeutic applications.

关键词： atopic dermatitis skin microbiota probiotic therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical characteristics and outcomes of psoriasis patients with COVID-19: A retrospective, multicenter cohort study in China

引用

中华医学杂志(英文版) 2024年第14期137卷 1736-1743页

作者： Liu Yanhua Xu Zhongrui Zhou Jian Chen Aijun Zhang Junling Kang Xiaojing Jiang Xian Lyu Chengzhi Shi Chunrui Shi Yuling Liu Xiaoming Li Fuqiu Yang Bin Huang Yongmei Yu Chen Wang Gang Department of dermatology Xijing Hospital Fourth Military Medical University Xi’an Shaanxi China Department of dermatology The First Affiliated Hospital of Chongqing Medical University Chongqing China Department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China Department of dermatology and Venereology People’s Hospital of Xinjiang Uygur Autonomous Region Urumqi Xinjiang China Department of dermatology West China Hospital Sichuan University Chengdu Sichuan China Department of Psoriasis Dalian Dermatosis Hospital Dalian Liaoning China Department of dermatology The First Hospital of Lanzhou University Lanzhou Gansu China Skin Disease Hospital of Tongji University Shanghai China Department of dermatology The University of Hong Kong-Shenzhen Hospital Shenzhen Guangdong China Department of dermatology The Second Hospital of Jilin University Changchun Jilin China Department of dermatology Dermatology Hospital of Southern Medical University Guangzhou Guangdong China Department of dermatology Xining First People’s Hospital Xining Qinghai China

Background: Limited information exists regarding the impact of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection on psoriasis patients. The objective of this study was to identify clinical factors associated with the prognosis of psoriasis following SARS-CoV-2 ***: A retrospective, multicenter study was conducted between March and May 2023. Univariable and multivariable logistic regression analyses were employed to identify factors associated with coronavirus disease 2019 (COVID-19)-related psoriasis outcomes. The study included 2371 psoriasis patients from 12 clinical centers, with 2049 of them having been infected with ***: Among the infected groups, lower exacerbation rates were observed in individuals treated with biologics compared to those receiving traditional systemic or nonsystemic treatments (22.3% [236/1058]vs. 39.8% [92/231]vs. 37.5% [140/373],P <0.001). Psoriasis progression with lesions (adjusted odds ratio [OR] = 8.197, 95% confidence interval [95% CI] = 5.685–11.820, compared to no lesions), hypertension (adjusted OR = 1.582, 95% CI = 1.068–2.343), traditional systemic (adjusted OR = 1.887, 95% CI= 1.263–2.818), and nonsystemic treatment (adjusted OR= 1.602, 95% CI= 1.117–2.297) were found to be associated with exacerbation of psoriasis after SARS-CoV-2 infection, but not biologics (adjusted OR = 0.931, 95% CI = 0.680–1.274, compared to no treatment), according to multivariable logistic regression ***: A reduced risk of psoriasis exacerbation after SARS-CoV-2 infection was observed with biologics compared to traditional systemic and nonsystemic treatments. Significant risk factors for exacerbation after infection were identified as existing psoriatic lesions and hypertension.

关键词： COVID-19 SARS-CoV-2 Psoriasis Treatment Biologics

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis:A multicenter,randomized,double-blind,placebo-controlled phase 2b trial

引用

Chinese Medical journal 2024年第2期137卷 200-208页

作者： Yan Zhao Jianzhong Zhang Bin Yang Jingyi Li Yangfeng Ding Liming Wu Litao Zhang Jinyan Wang Xiaohong Zhu Furen Zhang Xiaohua Tao Yumei Li Chunlei Zhang Linfeng Li Jianyun Lu Qingchun Diao Qianjin Lu Xiaoyong Man Fuqiu Li Xiujuan Xia Hao Cheng Yingmin Jia Guoqing Zhao Jinchun Yan Bo Chen Department of dermatology Peking University People’s HospitalBeijing 100044China Department of dermatology Dermatology HospitalSouthern Medical UniversityGuangzhouGuangdong 510091China Department of dermatology West China HospitalSichuan UniversityChengduSichuan 610041China Department of dermatology Shanghai Skin Disease HospitalInstitute of PsoriasisTongji University School of MedicineShanghai 200443China Department of dermatology Affiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhouZhejiang 310006China Department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China Department of dermatology Ningbo No.2 HospitalNingboZhejiang 315010China Department of dermatology The Wuxi Second Affiliated Hospital of Nanjing Medical UniversityWuxiJiangsu 214002China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of dermatology and Veneorology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China Center for Plastic&Reconstructive Surgery Department of DermatologyZhejiang Provincial People’s Hospital(Affiliated People’s HospitalHangzhou Medical College)HangzhouZhejiang 310014China Department of dermatology Affiliated Hospital of Jiangsu UniversityZhenjiangJiangsu 212001China Department of dermatology Peking University Third HospitalBeijing 100191China Department of dermatology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of dermatology The Third Xiangya Hospital of Central South UniversityChangshaHunan 410013China Department of dermatology Chongqing Traditional Chinese Medicine HospitalChongqing 400011China Hunan Key Laboratory of Medical Epigenomics Department of DermatologyThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of dermatology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China Departme

Background:Atopic dermatitis(AD)affects approximately 10%of adults ***310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 *** trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe ***:This multicenter,randomized,double-blind,placebo-controlled,phase 2b trial was conducted in 21 medical institutions in China from February to November *** 120 eligible patients were enrolled and randomized(1:1:1)to receive subcutaneous injections of 300 mg CM310,150 mg CM310,or placebo every 2 weeks for 16 weeks,followed by an 8-week follow-up *** primary endpoint was the proportion of patients achieving≥75%improvement in the Eczema Area and Severity Index(EASI-75)score from baseline at week *** and pharmacodynamics were also ***:At week 16,the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups(70%[28/40]for high-dose and 65%[26/40]for low-dose)than that in the placebo group(20%[8/40]).The differences in EASI-75 response rate were 50%(high ***,95%CI 31%-69%)and 45%(low ***,95%CI 26%-64%),with both P valuesdermatology Life Quality Index compared with ***310 treatment reduced levels of thymus and activation-regulated chemokine,total immunoglobulin E,lactate dehydrogenase,and blood *** incidence of treatment-emergent adverse events(TEAEs)was similar among all three groups,with the most common TEAEs reported being upper respiratory tract infection,atopic dermatitis,hyperlipidemia,and *** severe adverse events were deemed to be attributed to ***:CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tol

关键词： CM310 Moderate-to-severe atopic dermatitis Interleukin-4 receptor alpha Adults

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Eccrine porocarcinoma in the tempus of an elderly woman:A case report

引用

World journal of Clinical Cases 2024年第8期12卷 1523-1529页

作者： Zhi-Wei Wu Wen-Jie Zhu Shan Huang Qi Tan Cong You Dian-Gui Hu Long-Nian Li Department of dermatology First Affiliated Hospital of Gannan Medical UniversityGanzhou 341000Jiangxi ProvinceChina Department of Laser and Cosmetic dermatology Ganzhou Dermatology HospitalGanzhou 341000Jiangxi ProvinceChina Department of dermatology Tongxiang Dermatology HospitalJiaxing 314000Zhejiang ProvinceChina Department of Infectious Diseases The Fifth people’s Hospital of GanzhouGanzhou 341000Jiangxi ProvinceChina

BACKGROUND Eccrine porocarcinoma(EPC)is a rare skin tumor that mainly affects the elderly *** often present with slow growth and a good *** are usually distinguished from other skin tumors using histopathology and ***,surgical management alone may be inadequate if the tumor has ***,currently,surgical resection is the most commonly used treatment *** SUMMARY A seventy-four-year-old woman presented with a slow-growing nodule in her left temporal area,with no obvious itching or pain,for more than four *** examination showed small columnar and short spindle-shaped cells;thus,basal cell carcinoma was ***,immunohistochemical analysis revealed the expression of cytokeratin 5/6,p63 protein,p16 protein,and Ki-67 antigen(40%),and EPC was taken into *** skin biopsy was repeated,and hematoxylin and eosin staining revealed ductal differentiation in some ***,the patient was diagnosed with EPC,and Mohs micrographic surgery was *** adapted follow-up visits in a year and not found any recurrence of *** This case report emphasizes the diagnosis and differentiation of EPC.

关键词： Eccrine porocarcinoma Sweat gland carcinoma Histopathology Immunohistochemistry Prognosis Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Flow structure and shear stress in the presence of both ice cover on water surface and leafless vegetation in channel bed

引用

journal of Hydrodynamics 2024年第2期36卷 340-354页

作者： Mahboubeh Barahimi Jueyi Sui School of Engineering University of Northern British ColumbiaPrince GeorgeCanada

This study aimed to investigate the previously unexplored effects of ice cover and submerged vegetation on flow *** were undertaken under both open channel and ice-covered flow *** bed material consisted of three non-uniform *** findings revealed that when vegetation patches were present on the bed and an ice cover was present,the velocity profiles exhibited a distinctive pattern with two peak *** kinetic energy(TKE)also exhibited two peaks,one above the vegetation bending height and another at the sheath section,with a decreasing trend towards the ice ***,quadrant analysis showed that when the flow surface is covered by an ice cover,the contributions of inward and outward events increased compared with those observed in an open channel *** most cases,these contributions surpassed the sweep and ejection *** findings enhance our understanding of vegetation’s response to diverse surface conditions and have practical implications for river management and environmental engineering.

关键词： Ice cover vegetation flow structure Reynolds shear stress turbulent kinetic energy(TKE) quadrant analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expert Consensus on the Treat-to-Target Strategy for Psoriasis With Biological Agents in China(Simplified Edition)

引用

International journal of dermatology and Venereology 2024年第2期7卷 61-69页

作者： Ai-Jun Chen Da-Xing Cai Xiang Chen Yong Cui Yan Ding Heng Gu Xing-Hua Gao Chao Ji Xiao-Jing Kang Ye-Hong Kuang Cheng-Zhi Lyu Min Li Wei Li Xia Li Yu-Zhen Li Xiao-Yong Man Jian-Jun Qiao Juan Su Liang-Dan Sun Yu-Ling Shi Juan Tao Jian-Xin Xia Rong Xiao Bin Yang Wu Zhu Xue-Jun Zhang Committee on Psoriasis dermatology and Venereology Branch of the Chinese Medical Association Department of dermatology The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China Department of dermatology Qilu HospitalShandong UniversityJinanShandong 250100China Department of dermatology Xiangya HospitalCentral South UniversityChangshaHunan 410008China Department of dermatology China-Japan Friendship HospitalBeijing 100192China Department of dermatology Hainan Provincial Hospital of Skin DiseaseHaikouHainan 570311China Department of dermatology Hospital for Skin DiseasesChinese Academy of Medical SciencesNanjingJiangsu 210042China Department of dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110002China Department of dermatology The First Affiliated Hospital of Fujian Medical UniversityFuzhouFujian 350004China Department of dermatology People’s Hospital of Xinjiang Uygur Autonomous RegionUrumqiXinjiang Uyghur Autonomous Region 830001China Department of dermatology Dalian Dermatosis HospitalDalianLiaoning 116021China Department of dermatology Dushu Lake Hospital Affiliated to Soochow UniversitySuzhouJiangsu 215127China Department of dermatology West China Hospital of Sichuan UniversityChengduSichuan 610044China Department of dermatology Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Department of dermatology The Second Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150086China Department of dermatology The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310003China Department of dermatology The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310003China Department of dermatology The First Affiliated Hospital of Anhui Medical UniversityHefeiAnhui 230022China Department of dermatology Shanghai Skin Disease HospitalTongji University School of MedicineShanghai 200093China Department of dermatology The Union Hospital of Tongji Medical CollegeHuazhong University of Science and Te

Psoriasis is a chronic,recurrent,inflammatory systemic disease that is not only characterized by skin manifestations but may also be accompanied by various comorbidities,imposing a heavy burden on patients’physical and mental health and affecting their quality of *** the continuous approval of various biological agents for clinical use has provided more effective treatment options to patients with psoriasis,no consensus on the evaluation of comprehensive treatment goals has yet been *** treat-to-target(T2T)strategy requires consideration of multiple dimensions of treatment outcomes,the development of long-term management goals,and regular assessments of treatment conditions,which are often used in the management of chronic ***,based on the latest consensuses and guidelines,research data,and clinical experience as well as the combination of survey results and expert group discussions,the present consensus focuses on 4 dimensions of short-and long-term integrated management goals for biological agents:alleviating skin lesions,improving quality of life,screening and managing psoriasis comorbidities,and ensuring drug *** implementation methods,evaluation time,treatment monitoring,and program adjustments are also herein described to achieve comprehensive management of psoriasis to the maximum *** consensus provides a reference for clinical practice.

关键词： psoriasis biological agents treat-to-target comorbidity consensus

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of bilastine *** for the treatment of chronic idiopathic urticaria:A multicenter,double-blind,double-dummy,phase III,non-inferiority,randomized clinical trial

引用

Chinese Medical journal 2024年第12期137卷 1480-1482页

作者： Xue Chen Xiuping Han Bo Cheng Hui Li Lingling Liu Songmei Geng Linfeng Li Jie Li Qing Guo Guoyi Zhang Hong Fang Jianzhong Zhang Department of dermatology Peking University People’s HospitalBeijing 100044China Department of dermatology Shengjing Hospital of China Medical UniversityShenyangLiaoning 110055China Department of dermatology The First Affiliated Hospital of Fujian Medical UniversityFuzhouFujian 350004China Department of dermatology The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China Department of dermatology Peking University First HospitalBeijing 100034China Department of dermatology The Second Affiliated Hospital of Xi’an Jiaotong University(Xibei Hospital)Xi’anShaanxi 710006China Department of dermatology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of dermatology Xiangya HospitalCentral South UniversityChangshaHunan 410008China Department of dermatology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong 510120China Department of dermatology Hospital for Skin DiseasesChinese Academy of Medical SciencesNanjingJiangsu 210042China Department of dermatology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiang 310003China

To the Editor:Chronic urticaria,prevalent globally and increasing in China,predominantly affects young and middle-aged women,impacting their quality of life(QoL).[1]Standard treatment involves second-generation H1 antihistamines,with bilastine showing promise due to its selective action and minimal side ***,direct comparative studies are scarce,particularly in the Chinese *** aimed to evaluate the efcacy and safety of bilastine compared to levocetirizine in Chinese patients.

关键词： treatment double globally

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of Huzhang Granule,a compound Chinese herbal medicine,for acute gouty arthritis:A double-blind,randomized controlled trial

引用

journal of Integrative Medicine 2024年第3期22卷 270-278页

作者： Hao Wang Si-ting Chen Xiao-jie Ding Le Kuai Liang Hua Xin Li Yi-fei Wang Ming Zhang Bin Li Rui-ping Wang Mi Zhou Department of dermatology Yueyang Hospital of Integrated Traditional Chinese and Western MedicineShanghai University of Traditional Chinese MedicineShanghai 200437China Institute of dermatology Shanghai Academy of Traditional Chinese MedicineShanghai 201203China Department of dermatology the Affiliated Hospital of Jiangxi University of Chinese MedicineNanchang 330000Jiangxi ProvinceChina Shanghai Skin Disease Hospital School of MedicineTongji UniversityShanghai 200443China Institute of dermatology School of MedicineTongji UniversityShanghai 200443China

Background:Acute gouty arthritis(AGA)is an inflammatory joint disease with a high *** medical interventions,including nonsteroidal anti-inflammatory drugs,colchicine and glucocorticoids,can have serious adverse *** Granule(HZG),a compound Chinese herbal medicine,has been used to treat AGA for more than 30 years with satisfactory effects and no significant adverse ***,the efficacy and safety of HZG in AGA patients remains ***:The present investigation was designed to examine the efficacy and safety profile of HZG in managing AGA ***,setting,participants and interventions:The current study was conducted as a noninferiority,randomized controlled clinical trial on 180 eligible enrolled *** were randomly assigned into the HZG and etoricoxib *** were administered for 5 d,during which the HZG group received HZG and placebo etoricoxib,while the etoricoxib group received etoricoxib and placebo HZG in the same ratio(1:1).Main outcome measures:The primary outcome was pain experienced by the patient in the gout-afflicted joint from days 2 to 5 of the treatment *** pain level was measured via a visual analogue scale,ranging from 0 mm to 100 *** secondary outcomes comprised joint tenderness and swelling,reduction of inflammatory biomarkers,and the patient’s and investigator’s global evaluations of therapeutic ***:The mean reduction in pain was-51.22 mm(95%confidence interval[CI],[-53.42,-49.03]mm)for the HZG and-52.00 mm(95%CI,[-54.06,-49.94]mm)for the etoricoxib *** mean difference between the two groups was 0.78 mm(95%CI,[-2.25,3.81]mm).All additional efficacy endpoints,covering decreased inflammation and pain relief,yielded compelling proof of *** in the HZG group exhibited a comparatively lower rate of adverse events compared to those in the etoricoxib group(4.44%vs 13.33%;P≤0.05).Conclusion:HZG and etoricoxib groups demons

关键词： Acute gouty arthritis Huzhang Granule Randomized controlled trial Blind

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chinese expert consensus on the diagnosis and treatment of balanoposthitis

引用

Chinese Medical journal 2024年第13期137卷 1519-1521页

作者： Li Zhang Amer A.A.Abdulrahman Hao Guo Jia’an Zhang Xinghua Gao Weihua Pan Gang Wang Jinhua Xu Yuling Shi Liuqing Chen Hongxiang Chen Songmei Geng Yuping Ran Hongwei Wang Xiaoyong Man Jianmin Chang Furen Zhang Litao Zhang Guangwen Yin Jianzhong Zhang Wei Lai Zhibin Niu Hongkun Jiang Haibo Liu Yaolong Chen Jianjian Wang Department of dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Key Laboratory of Immunodermatology Ministry of Education and NHCNational Joint Engineering Research Center for Theranostics of Immunological Skin DiseasesShenyangLiaoning 110001China Department of dermatology Chinese Academy of Medical Science and Peking Union Medical CollegeNanjingJiangsu 210042China Department of dermatology Second Affiliated Hospital of Naval Medical UniversityShanghai 200003China Department of dermatology Xijing HospitalFourth Military Medical UniversityXi’anShaanxi 710032China Department of dermatology Huashan HospitalFudan UniversityShanghai 200040China Department of dermatology Shanghai Skin Disease HospitalTongji University School of MedicineShanghai 200443China Department of dermatology Wuhan No.1 HospitalWuhanHubei 430022China Department of dermatology Huazhong University of Science and Technology Union Shenzhen HospitalShenzhenGuangdong 518052China Department of dermatology Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China Department of Dermatovenereology West China HospitalSichuan UniversityChengduSichuan 610041China Department of dermatology Huadong HospitalFudan UniversityShanghai 200040China Department of dermatology Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China Department of dermatology Beijing HospitalBeijing 100730China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of dermatology and Venereology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250061China Department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China Department of dermatology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China Department of dermatology Peking University People’s HospitalBeijing 100044 China Department of dermatology Third Affi

Balanoposthitis(BP),a common male genitalia inflammation,is managed by clinicians from different specialties,including urology,pediatrics,dermatology,and *** to this diverse array of clinicians involved,there exists a lack of consistent,evidence-based recommendations for *** development of the consensus engaged 19 representative hospitals and it adhered to rigorous protocols,encompassing international registration(IPGRP-2021CN003)and the application of evidence grading criteria and recommendation standards[Appendix S1,Supplementary File,http://***/CM9/C42].Over the period from December 2020 to October 2022,consensus on 12 clinical issues was reached through comprehensive evidence searches and two iterations of Delphi surveys[Supplementary File,http://***/CM9/C42].

关键词： Delphi diagnosis rigorous

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：